Abstract
Low-grade gliomas are the most common brain tumour to occur in childhood. The identification of the mitogen-activated protein kinase pathway as the near-uniform driver of these tumours has led to the testing of therapies targeted at this pathway, with promising early results. The pan-RAF inhibitor tovorafenib is one of the most recent targeted agents to be tested for paediatric low-grade gliomas, with early data raising the prospect that we may be at the dawn of a new era in the management of this childhood brain tumour.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.